Serum uric acid is positively associated with the prevalence of nonalcoholic fatty liver in non-obese type 2 diabetes patients in a Chinese population

2021 ◽  
Vol 35 (5) ◽  
pp. 107874
Author(s):  
Yuliang Cui ◽  
Jing Liu ◽  
Haiyan Shi ◽  
Wenmei Hu ◽  
Li Song ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Uric Acid ◽  
Fatty Liver ◽  
Serum Uric Acid ◽  
Chinese Population ◽  
Nonalcoholic Fatty Liver ◽  
Diabetes Patients

Association of HbA1c, Serum Uric Acid and Non-HDL Cholesterol in Type 2 Diabetes Patients

Metabolism ◽  
2020 ◽  
Vol 104 ◽  
pp. 154063
Author(s):  
Sushil Baral ◽  
Rupesh Kshetri ◽  
Laxman Mandel
Keyword(s):  
Type 2 Diabetes ◽  
Uric Acid ◽  
Serum Uric Acid ◽  
Hdl Cholesterol ◽  
Diabetes Patients

scholarly journals The Effect of Sodium Channel Blocker, Mexiletine, on Body Weight in Type 2 Diabetes Patients with Visceral Obesity

2019 ◽  
Vol 12 ◽  
pp. 117955141882504
Author(s):  
Naohiko Ueno
Keyword(s):  
Type 2 Diabetes ◽  
Body Weight ◽  
Uric Acid ◽  
Waist Circumference ◽  
Diabetic Neuropathy ◽  
Serum Uric Acid ◽  
Visceral Obesity ◽  
Control Group ◽  
Diabetes Patients

Objective: Mexiletine is an anti-arrhythmic agent also used for the treatment of painful diabetic neuropathy. In this study, the effect of mexiletine on body weight was evaluated in type 2 diabetes patients with diabetic neuropathy exhibiting visceral obesity. Methods: Type 2 diabetes patients with neuropathy exhibiting visceral obesity (n = 21) treated by mexiletine (300 mg/day) and a control group of type 2 diabetes patients with the same condition who received vitamin B12 (n = 12) were retrospectively evaluated. Body weight, waist circumference, hemoglobin A1c (HbA1c), blood pressure, liver function, serum lipids, and serum uric acid were assessed before and 6 months after the treatment. Results: Mexiletine significantly decreased body weight and waist circumference. The changes in body weight and waist circumference in 6 months in the mexiletine group were greater than in the control group. In metabolic parameters, there were significant decreases in triglyceride (TG) and serum uric acid. There were positive relationships between the change in body weight and the changes in TG, uric acid, alanine aminotransferase (ALT), and HbA1c. Conclusions: Mexiletine may affect body weight regulation. It ameliorated the metabolic parameters possibly by decreasing visceral fat. Further study should be performed to clarify the mechanism of the effect.

scholarly journals Relationship between serum uric acid level and nonalcoholic fatty liver disease in type 2 diabetes patients

Medicine ◽  
2021 ◽  
Vol 100 (33) ◽  
pp. e26946
Author(s):  
Haifeng Yu ◽  
Ling Zhao ◽  
Lijuan Liu ◽  
Yanfang Li ◽  
Jing Sun ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Uric Acid ◽  
Liver Disease ◽  
Fatty Liver ◽  
Uric Acid Level ◽  
Fatty Liver Disease ◽  
Acid Level ◽  
Serum Uric Acid Level ◽  
Nonalcoholic Fatty Liver

scholarly journals The Association between Serum Uric Acid and Residualβ-Cell Function in Type 2 Diabetes

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Wei Tang ◽  
Qi Fu ◽  
Qingqing Zhang ◽  
Min Sun ◽  
Yuan Gao ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Uric Acid ◽  
Insulin Secretion ◽  
Serum Uric Acid ◽  
Cell Function ◽  
Linear Regression Analysis ◽  
Oral Glucose ◽  
Sensitivity Index ◽  
Diabetes Patients

The aim of this study was to investigate the relationship of serum uric acid (sUA) with residualβ-cell function in type 2 diabetes. Oral glucose tolerance tests (OGTT) were performed on 1021 type 2 diabetes patients. The ratio of area under curve of insulin to glucose during 0 to 30 min and 0 to 120 min of the OGTT was calculated as indices of insulin secretion function. The products of insulin secretion indices multiplied by Matsuda insulin sensitivity index were used as disposition indices. After correlation and multiple linear regression analysis, sUA was significantly associated with insulin secretion and disposition indices in male, female, and total groups adjusted for confounding factors (including metabolic indicators like sex, age, course of the disease, blood glucose, blood pressure, serum lipids, and so on). Superficially steeper time-dependent decline of insulin secretion function was found in patients with sUA above the median than those below it. In conclusion, our results suggest an independent positive association between sUA and residualβ-cell function in type 2 diabetes. Patients with higher sUA have greater insulin secretion ability than those with lower sUA at the early stage of disease, but their residualβ-cell function seems to decay more rapidly.

Sign in / Sign up

Export Citation Format

Share Document